← All trials
NCT06122870
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 4, 2023
- Primary completion
- Feb 29, 2024
- Completion date
- Feb 28, 2025
- First posted
- Nov 8, 2023
- Last posted
- Dec 14, 2023
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Johns Hopkins UniversityLead sponsor
- United States NavyCollaborator
- Johns Hopkins UniversityOverall official - principal investigator
- Department of DefenseCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.